Stockreport

Zomedica Corp (ZOM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ... [Yahoo! Finance]

Zomedica Corp. Common Shares  (ZOM) 
US:NYSE Investor Relations: investors.zomedica.com
PDF Diagnostics Segment Revenue: Approximately $500,000, an increase of 38%. Gross Margin: 72.3%, higher than last year's 69%. Operating Expenses: $12.5 million, an inc [Read more]